Navigation Links
Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
Date:3/10/2008

f Labopharm's twice-daily tramadol-acetaminophen combination product to placebo in the treatment of acute low back pain. The study, which is being conducted at more than 20 centers in the U.S. and Canada, has a treatment period of approximately one week and is expected to include more than 250 patients.

About the Acute Pain Prescription Market

The number of prescriptions written for acute pain products (mild-opioids, tramadol, COX-2 inhibitors, non-steroidal anti-inflammatory drugs and combinations forms of these products) in the U.S. alone in 2007 grew to 290 million and accounted for sales of US$9.0 billion.

About Tramadol-Acetaminophen Combination Products

Tramadol-acetaminophen combination products offer the analgesic strength of tramadol and the rapid analgesia of acetaminophen in a single tablet. Tramadol-acetaminophen combination products were first launched in 2001 in the United States and in 2003 in other major markets and are indicated for the short-term (five days or less) management of acute pain in the US and the symptomatic treatment of moderate to severe pain in the rest of the world. Tramadol-acetaminophen combination products are currently available only in formulations that must be administered four- to six-times per day.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become a fully integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... To help healthcare organizations ... practices compliantly and profitably, MDreferralPRO and Vericle ... The interoperability between a strategic referral management ... management system is necessary for a healthcare ... referral management and development solution relies on ...
(Date:3/1/2015)... Orion, Metamora, Michigan (PRWEB) March 01, 2015 ... is approved to treat Overactive Bladder (OAB) symptoms, such as ... in adults when another type of medication (anticholinergic) does not ... a different treatment option that takes another approach to targeting ... , BOTOX® works on the nerves and bladder muscle, blocking ...
(Date:3/1/2015)... 01, 2015 A federal court ... ) scheduled to go to trial in October ... witness to provide testimony regarding the role an ... the Profemur device, Bernstein Liebhard LLP comments. According ... Northern District of Iowa on February 25th, Wright ...
(Date:3/1/2015)... GA (PRWEB) March 01, 2015 ... Evelyn King and Carolyn Roddy to the professional staff ... of Compliance, graduated from The Ohio State University-Mortiz College ... 15 years of experience working with several Fortune 500 ... in the area of corporate benefits. Her experiences range ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The MCA ... across Malaysia into one platform and gears towards the ... , A series of group talks in smaller groups ... Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social ... raise awareness of Malaysian youths. , Young ...
Breaking Medicine News(10 mins):Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4
... have found that Nepali rhesus is by all means ... currently been used in biomedical research. // The Nepali ... prevailing shortage of laboratory animals used for developing of ... of the current issue of the American Journal of ...
... introduction of a UN AIDS report, UN officials were prompted ... in Myanmar and Vietnam // , which is inadequate prevention ... was originally a HIV/AIDS haven, has shown remarkable decline in ... measures to combat AIDS go slack, there is a risk ...
... the warmth of summer, mosquitoes too are out to suck ... could mean a lethal injection of many harmful diseases//. ... that Delaware offers an ambient atmosphere for mosquito to breed. ... top 10 in the United States in human population density ...
... to 24-year-old adults in UK revealed that above half of them ... intoxicate, about 18 per cent of people from all ages in ... cent of people in UK, who were aged between 18-24 and ... – said doctors. ,In Scotland nearly 27 per cent ...
... have agreed to cooperate in sharing key intelligence inputs ... drugs trafficking and assist each other in disaster management. ... intelligence and information in these key security-related areas and ... of disaster management," a senior official told PTI Wednesday ...
... agitating medicos today on the future course of their anti-reservation// ... Court to resume duties immediately. ,A section of ... strike to honor the apex court direction, while others say ... was not addressed to medical students., ,Sources said heated ...
Cached Medicine News:Health News:Nepali Rhesus May be Used as an Alternate for HIV/AIDS Research 2Health News:Nepali Rhesus May be Used as an Alternate for HIV/AIDS Research 3
(Date:3/2/2015)... 2015   , Boston Scientific to ... consideration of up to $1.65 billion, with $1.6 billion in ... alternatives for AMS, Women,s Health business , ... business Endo International plc (NASDAQ: ... into a definitive agreement with Boston Scientific (NYSE: ...
(Date:3/2/2015)...  BioMed Realty Trust, Inc. (NYSE: BMR ... feet of space in the most dynamic and valuable ... the termination of Vertex Pharmaceuticals, leases on three properties ... 28, 2015. BioMed Realty will receive a $14 million ... reposition the properties to meet the growing demand for ...
(Date:3/1/2015)... , March 1, 2015  An innovative interventional ... migraine sufferers sustained relief of their headaches, according ... of Interventional Radiology ,s Annual Scientific Meeting ... State University New York Empire State College in ... sphenopalatine ganglion (SPG) blocks to give patients enough ...
Breaking Medicine Technology:Endo Announces Divestiture of American Medical Systems' Men's and Prostate Health Businesses to Boston Scientific 2Endo Announces Divestiture of American Medical Systems' Men's and Prostate Health Businesses to Boston Scientific 3BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District 2BioMed Realty Gets Back 313,000 Square Feet Of Valuable Real Estate In Cambridge Innovation District 3Image-guided treatment shown to break the migraine cycle 2Image-guided treatment shown to break the migraine cycle 3Image-guided treatment shown to break the migraine cycle 4
... of Proprietary siRNA Molecule in Acute ... ... Inc., a,development-stage pharmaceutical company focused on discovering and,developing novel RNA interference-based ... its proprietary product,candidate, AKIi-5, a siRNA compound discovered and developed by ...
... 16 AstraZeneca (NYSE:,AZN) today announced that the ... SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release,Tablets for maintenance treatment ... the FDA approved SEROQUEL XR for the acute ... experience high rates of symptom relapse, and as,a ...
Cached Medicine Technology:Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 3Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 4SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 2SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 3SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 4SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 5SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 6SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 7SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 8
Phaco-emulsification systems CV series...
The unprecedented power, flexibility and versatility of the Series 20000 Legacy have made it the world's leading phacoemulsifier....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Medicine Products: